



Properties of *Candida albicans* Biofilms: An Update

Milind Davane, Basavraj Nagoba*, Asha Pichare, Pradeep Kendre

Department of Microbiology, MIMSR Medical College, Latur, India

Abstract

Biofilm formation in *Candida albicans* is one of the important virulence factors causing infections refractory to antimicrobial agents. The factors responsible for increased resistance include complex architecture of biofilms, its matrix, increased efflux pumps and metabolic plasticity. Uses of various medical devices are associated with *C. albicans* biofilms. This review focuses on different aspects of *Candida albicans* biofilms. These include formation of four temporal stages, several important factors affecting biofilm formation, their resistance to commonly used antifungal agents including azoles and polyenes, the mechanism of resistance and alternative approaches inhibiting formation of biofilms (potential antibiofilm drugs). In conclusion, the detailed review of various aspects of *Candida* biofilms provide in depth insight of biology and pathogenesis caused by *Candida* biofilm. This detailed knowledge will certainly help in the better management of diseases associated with biofilm formation.

Keywords: *Candida albicans*; Biofilms; Resistance

Introduction

Amongst all, biofilm formation is one of the important virulence factors causing infections refractory to antimicrobial agents [1-3]. Biofilms are defined as communities of sessile organisms irreversibly associated with a surface, encased within a polysaccharide-rich extracellular matrix and exhibiting enhanced resistance to antimicrobial agents [4-6]. Biofilms are formed on both biotic and abiotic surfaces. Mature biofilms are much more resistant to antimicrobial agents and host immune factors in comparison to planktonic cells. The factors responsible for increased resistance include complex architecture of biofilms, its matrix, increased efflux pumps and metabolic plasticity [7,8].

Candida spp. is most common cause of fungal nosocomial bloodstream infections. Among *Candida* spp. *Candida albicans* is most prevalent species involved in nosocomial bloodstream infections. In spite of advanced antifungal therapy available, the mortality due to candidiasis was found to be 50 percent in adults and 30 percent in children [9,10].

OPEN ACCESS

*Correspondence:

Basavraj Nagoba, MIMSR Medical College, Latur, Maharashtra, Latur, India,
Tel: 912382227587;

E-mail: dr_bsnagoba@yahoo.com

Received Date: 30 Mar 2018

Accepted Date: 24 Apr 2018

Published Date: 01 May 2018

Citation:

Davane M, Nagoba B, Pichare A, Kendre P. Properties of *Candida albicans* Biofilms: An Update. *Am J Clin Microbiol Antimicrob*. 2018; 1(4): 1017.

Copyright © 2018 Basavraj S Nagoba. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Many studies have been done on bacterial biofilms, but biofilms of *Candida* spp. have been studied less. Use of various intravascular medical devices is associated with nearly half of the cases of nosocomial infections. Central venous catheters, urinary catheters, pacemakers, mechanical heart valves, joint prosthesis, contact lenses and dentures are all susceptible to *C. albicans* biofilm [11-14].

Central venous catheters are considered as the most common risk factor for development of candidemia [15]. Once the biofilm is formed on implanted medical devices, *Candida* biofilm has potential to seed disseminated bloodstream infections leading to invasive systemic infections. These medical devices associated infections may become disastrous. Also, management of these infections is difficult and costly.

The study of impact of *Candida* infections of medical devices including various vascular catheters, joint prosthesis, dialysis access (hemodialysis fistulas, hemodialysis grafts, peritoneal dialysis catheters), cardiac devices, central nervous system devices, urinary catheters, penile implants demonstrated differences in rate of infection, mortality, risk factors and species of *Candida* involved. Although removal of most of the devices to achieve cure in these patients had been suggested earlier [13], use of antibiotic-impregnated prosthesis, coating of catheters with antimicrobials, selective decontamination with topical non-absorbable antibiotics, preventive antibiotic lock technique, prophylactic peri-operative antibiotics, etc. have been recommended in recent European Society for Clinical Microbiology and Infectious Diseases (ESCMID) guidelines [16].

Recent advances in technology have developed novel approaches to investigate biofilms and to identify specific markers for biofilms. Specific genes with specific pattern of gene expression have been reported in *C. albicans* biofilms. Analysis of these genes can be performed by using techniques like

micro-array analysis with probe. Alternatively Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), e.g. an RT-PCR assay can be used to analyse expression pattern of Agglutinin-Like Sequence (ALS) genes in *C. albicans* biofilms. In addition gene analysis, proteomic analysis of biofilm specific proteins can also be carried out e.g. phase-specific cell wall proteins expressed during the formation of biofilm can be separated using two-dimensional gel electrophoresis which can be further digested to peptides and the digested peptides can be identified by Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) mass spectrometry [17].

In this review, different aspects of *Candida* biofilms are evaluated.

Formation of Biofilms

The biofilms formed *in vitro* are composed of fungal cells embedded in polysaccharide rich extracellular matrix.

Candida biofilm matrix is mainly composed of carbohydrates, proteins, phosphorus and hexosamines, whereas *Candida* biofilm cell also consisted of yeast form cells (blastospores) and long tubular hyphae as well as pseudohyphae, and it associated with dimorphic switch between yeast and hyphal growth.

When formed *in vivo* or on *in vitro* devices like intravascular catheters, urinary catheters, these biofilms also contain host-derived biomolecules such as dead cells, fibrinogens, etc.

Formation of biofilms occurs in a sequential process. *C. albicans* biofilm formation comprises four temporal stages, *viz* adherence to surface, proliferation to form a basal layer of anchoring cells, growth of pseudohyphae and hyphae concomitant with production of extracellular matrix material and slow dispersal of yeast form of cells from biofilm to seed new sites [18-21].

The process of adherence to biomaterials is mediated by non-specific factors such as hydrophobicity of cell surface and electrostatic forces as well as by specific ligands (adhesions on fungal cell surface) such as serum proteins (fibrinogen and fibronectin) and salivary factors. As per the recent study the specific attachment to biomaterials may also be mediated by cell surface proteins encoded by members of the ALS family of adhesion-producing genes and EAP1 [22]. This initial attachment of yeast cells to the substrate is followed by cell division, proliferation of these yeast cells and development of biofilm.

Various workers used scanning and transmission electron microscopy to study the morphology of biofilms formed by *Candida* spp. [20,23]. The structure of biofilms varies depending on the substrate on which it forms. These differences may be attributed to differences in substrate properties and nutritional conditions. The fluorescent and confocal microscopies are also used to reveal the structure of biofilms.

Factors affecting biofilm formation

The various factors affecting biofilm formation include:

Fluid flow: Physiological conditions such as fluid flow at the site of infection influences and modulates the nutrient exchange and structural integrity of biofilms [24-26]. *Candida* biofilms formed under flow produces more extracellular matrix compared to those formed under static conditions.

Substrate: Several studies demonstrated the role of substrate in modulating the ability of *Candida* to form biofilm. Different substrates can greatly influence the architecture, morphology and thickness of

biofilm. It has been found that biofilms formed by *Candida albicans* was slightly increased on latex or silicone elastomer as compared to polyvinyl chloride. It was substantially decreased on polyurethane or 100% silicone [20,27].

Nutrients: Nutrients particularly sugars, lipids and serum are crucial determinants of biofilm forming ability of *Candida*. The biofilm forming ability has been found to be increased in presence of sucrose [28], glucose [20], lipid emulsion [29] and human serum [30].

Species variability: The ability to form biofilm may vary within the strains of different *Candida* spp. The biofilms formed by *C. parapsilosis*, *C. pseudotropicalis* and *C. glabrata* were significantly less than more pathogenic *C. albicans* [20]. It has been reported that the amount of biofilms formed on catheter by *C. parapsilosis*, *C. glabrata* and *C. tropicalis* is less in volume as compared to biofilms formed by *C. albicans* and also, there is difference in architecture between these [31]. These results demonstrate that the biofilm forming ability, structure and matrix composition are highly dependent on species of *Candida*. In general, *C. albicans* produces quantitatively larger and qualitatively more complex biofilm than other species.

Microbial cohabitants: Studies on the interaction between *C. albicans* and bacteria in polymicrobial biofilm show that secretion of signaling molecules that influence the behavior of one species towards other, by direct cell to cell physical contact and by alteration of local environment such as change in pH and oxygen concentration. These interactions are clearly of great importance and interest with relevance to human health. The ability of *Candida* to form biofilm is also affected by presence of additional *Candida* species or of different bacterial cohabitants, e.g. two common oral fungi i.e. *C. albicans* and *C. tropicalis* bind to *Streptococcus gordonii* while two other *Candida* species i.e. *C. krusei* and *C. kefyr* do not [32]. It has also been found that the presence of lactobacillus on fibre and uroepithelial cells affect the ability of biofilm formation by *Candida* [33]. A reduction in biofilm formation of *C. albicans* when this fungus is added to preformed biofilms of non-*albicans* *Candida* and bacteria [34]. The studies on interaction between *Pseudomonas aeruginosa* and *C. albicans* showed that *P. aeruginosa* formed a dense biofilm on *C. albicans* filaments and killed the fungus. On the contrary, *P. aeruginosa* neither bound nor killed the yeast form of *C. albicans* [35]. In general, co-culturing of *C. albicans* with bacteria reduces the biofilm forming ability of *C. albicans* [36].

The host products like salivary adhesins as well as microbial proteins have been proposed to be involved in the mechanisms of these interactions in biofilms. Fatty acid signaling molecule and trans-2-decenoic acid (SDSF) produced by *S. mutans* could affect biofilm architecture [37]. Several virulence factors of *P. aeruginosa* including homoserine lactones and phenazine (pyocyanin) are involved in inhibition of *Candida* biofilm [35,38,39]. These earlier studies demonstrate that the interactions between fungus-fungus and fungus-bacteria play critical role in modulating the ability of *C. albicans* to form biofilm.

Candida products: Studies based on target gene disruption, microarray-based transcriptomics, proteomics and genomics demonstrate that several genes, proteins and metabolites play significant roles in maintenance of biofilm phenotype by *Candida*. In first proteomic analysis of *Candida* biofilm, it was found that protein; alcohol dehydrogenase was involved in modulating the biofilm. *Candida* genes implicated in biofilm formation include ACE2,

YWP1, HWP1, LL34 (RIX7), ALS3, GAL10, VPS1, SUR7, GUP1, PEP12, TPK1/2, NRG1 (transcriptional repressor) and its target BRG1 (GATA family transcription factor), UME6 (transcriptional regulator), HGC1 (a cyclin-related protein), SUN41 (a putative cell wall glycosidase), EFG1, STV1 and VPH1 (Golgi/vacuolar subunits of vacuolar proton-translocating ATPase isoforms), CEK1 (map kinase), BCR1, SPT20, SAC1 (PIP phosphatase) and the novel transcriptional factors such as Ndt80, Rob1 and Brg1 [40-58].

Extracellular matrix production is controlled by additional factors. β -1,3 glucan is the major component of biofilm matrix. The zinc-responsive transcriptional factor Zap1 negatively regulates β -1,3 glucan. Glucan transferases (Bg12 and Phr1), glucoamylases (Gca1 and Gca2) and exo-gluconase, Xog1 are positive regulators of β -1,3 glucan production [59,60]. Furthermore, recent studies have shown that *C. albicans* biofilms were resistant to killing by neutrophils and also don't trigger the production of Reactive Oxygen Species (ROS) [61].

Additionally, quorum sensing molecules such as 3R-Hydroxy-Tetradecaenoic Acid (3R-HTDE) [62], farnesol [63] and cis-2-dodecenoic acid (BDSF) [64] also play significant role in Candida biofilm formation.

Certain metabolic processes such as carbohydrate assimilation, amino acid metabolism and intracellular transport [65] and glycolytic flux and hypoxia adaptation [66] have been suggested to have critical role in Candida biofilm formation. The mechanisms by which these proteins, genes modulate the biofilm formation are currently being investigated.

Antifungal Susceptibility Profile of Candida Biofilms

Although there is variation in susceptibility pattern of Candida biofilms to various antifungal agents, resistance has been frequently reported against commonly used antifungal agents. Candida biofilms have been found to be resistant to commonly used antifungal agents including azoles and polyenes [67-69]. In contrast to biofilms, planktonically grown *C. albicans* has shown susceptibility to most of the antifungal agents. In some earlier reports, amphotericin B, echinocandins and voriconazole have been reported to be active against Candida biofilms [70,71].

Scanning electron microscopy and confocal scanning laser microscopy demonstrated that caspofungin affected cellular morphology within biofilms. Coating of biomaterial with caspofungin had an inhibitory effect on subsequent development of *C. albicans* biofilm. Aminocandin, a newer echinocandin also showed antibiofilm properties [72]. In a recent study on time-lapse microscopic observation of effect of micafungin and fluconazole on Candida biofilm formed on silicon disks in RPMI medium, both drugs have shown inhibitory effect on Candida biofilm with relative differences in time of their action on biofilms [73].

Currently several agents are under investigation as potential antibiofilm drugs for Candida biofilm. These include chlorhexidine, sodium hypochlorite, zosteric acid, filastatin, EDTA/ethanol catheter lock solutions, gentian violet and essential oils [74-79]. Additionally physical interventions such as low-level laser [80], photodynamic therapy [81] and antimicrobial coating of catheters [13] have also been proposed as possible therapeutic alternatives. However, more detail studies are warranted to determine efficacy of these agents

against Candida biofilms.

Mechanisms of Resistance of Candida Biofilms

Various models developed, allowed detailed understanding of mechanisms of resistance to *C. albicans* biofilms. The methods include studying alterations in drug target involving changes in membrane sterol, membrane localized drug efflux pump assay at functional and transcriptional level and reduced or limited drug penetration through biofilms.

The alteration in sterol composition is linked to antifungal resistance. The modulation in the level of sterols may contribute to drug resistance in phase-specific manner [82]. The role of efflux pump in biofilm associated resistance has also been reported [83]. Persister cells are another contributor to drug resistance property of biofilm. These are phenotypic variants of a minor subset of metabolically dormant yeast cells. Persister cells are extremely resistant to antifungal drugs [84].

Antibiofilm Strategies: Perspectives, Research and Development

A better understanding of mechanism of formation of biofilm and its maintenance could lead to development of new antifungals that specifically target a particular state of biofilm. The susceptibility of Candida biofilms to the current therapeutic agents remains low, with exception of echinocandins. These agents are applied in different approaches as alternative methods. The perspectives of usage are:

Lock therapy approach

This approach is currently recommended and employed in treating catheter related bloodstream infections particularly in use of long term catheters according to the guidelines of the Infectious Disease Society of America [85]. The lock therapy involves the instillation of high doses of antimicrobial agents from 100-1000 fold the Minimum Inhibitory Concentration (MIC) directly into the catheter in order to 'lock' it for certain period of time from hours to days [86]. Although lock therapy does not promise to achieve 100 percent biofilm inhibition, few reports are promising for potential use of lock technique to treat infected catheters. The results of use of lock therapy seems promising but not yet convincing on cost effective point of view as huge dosages are still needed to eradicate fungal growth.

Material coating and novel anti-biofilm surfaces

A developing field of research focuses on the usage of modified materials or coated surfaces. This prevents adherence and biofilm development. Surface characteristics of implants such as surface roughness, chemistry, free energy can influence the type and feature of biofilm [87]. For example, in *Candida albicans*, the adhesion to denture material is increased if its roughness is enhanced [88]. Thus, surface modifications and surface coating with antifungal agents help to inhibit the Candida biofilm.

Quorum sensing molecules and natural by-products

Several quorum sensing molecules and natural by-products have been shown to influence the Candida biofilm formation. The examples are physical and chemical signals from oral bacterium *Streptococcus gordonii* modulates adhesion and biofilm formation by *C. albicans*.

Farnesol, a sesquiterpene and signaling molecules produced by *C. albicans* repress biofilm formation *in vitro* [89]. Tyrosol

accelerates hypha production in early stage of biofilm development [90]. Homoserine lactone produced by *Pseudomonas aeruginosa* represses *C. albicans* filamentation [35]. Also phenazine produced by *Pseudomonas* has exhibited antifungal activity against *C. albicans*. In a different approach, Valle, et al. demonstrated the polysaccharides produced by commensal organisms antagonize biofilm formation [91].

The identification and alteration of the communication signals would certainly help in better understanding of species co-existence and permit a better control of biofilm [92]. Targeting quorum sensing molecules in research could help in finding the novel anti-biofilm agents [93].

Host response to biofilm: Perspective of Immunotherapy

Although immune response is complex, immunotherapy has great potential against infections [94]. Little is known about the interaction between human phagocytes and *Candida* biofilm. However, immunotherapeutic treatment against candidiasis has been undertaken [95].

C. albicans and *C. parapsilosis* biofilm were found more susceptible to the additive effects of phagocytic host defense and echinocandin anidulafungin than to each separately and to the combination of the azoles, voriconazole with phagocytes [96,97].

Dectin 1, a receptor for β -glucan found on phagocytes is required for fungal killing and induction of early inflammatory response. This finding is of great interest for biofilm recognition by immune system as β -1,3 glucan are found in high amounts in extracellular matrix of *Candida* biofilm *in vitro* and *in vivo* [98].

Immunotherapeutic strategies such as vaccination, anti-candida antibodies and cytokine therapy are under investigation to treat *Candida* infection [99]. However, their application to treat *Candida* biofilm is still in preliminary stage. In relation to this, antibody based approach was studied which showed to have reduced adhesion and biofilm formation *in vitro* [100]. *In vivo* studies of antibody approach remain to be investigated in context of biofilm.

Experimental Models of Candida Biofilm

Microbial biofilm formation is multistep process involving physical, chemical and biological changes [101]. To study the versatility of *Candida* biofilm in humans, it is necessary to develop *in vitro* and *in vivo* models, which provide similar situation for formation of biofilm. It is also necessary to develop models that demonstrate common and specific characteristics of *Candida* biofilm morphology. Various models have been studied to investigate the properties of biofilm *in vitro* [19]. These range from simple assays with catheter discs to more complex flow systems such as the perfused biofilm fermenter or reactor and shear stress rotating disc system [66,102]. Subsequently various *in vitro* models have studied biofilm formation on variety of articles like plastics, microtitre plate, biofilm chips formed on glass slide, Calgary film devices, microporous membrane cellulose filters, acrylic strips, voice prosthesis, catheter discs, contact lenses and tissue culture flasks. Although biofilm formation takes place on variety of substrates, clinically relevant substrates like catheter, denture acrylic strips, voice prosthesis and contact lenses show similarity to clinical settings under physiological conditions than those formed on non-physiologically relevant substrates. *In vivo* models not only include abiotic substrates like catheters in rat, mouse and rabbit, denture in rat, contact lens in mouse but also

biotic surfaces such as oral cavity, oropharyngeal mucosa, tongue and vaginal mucosa in mouse [18,103-107].

Conclusion

The detailed review of various aspects of *Candida* biofilms provide in depth insight of biology and pathogenesis caused by *Candida* biofilm. This detailed knowledge will certainly help in the better management of diseases associated with biofilm formation.

References

1. Donlan RM. Biofilms and device-associated infections. *Emerg Infect Dis.* 2001;7(2):277-81.
2. Donlan RM. Role of biofilms in antimicrobial resistance. *ASAIO J.* 2000;46(6):S47-52.
3. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Standardized method for *in vitro* antifungal susceptibility testing of *Candida albicans* biofilms. *Antimicrob Agents Chemother.* 2001;45(9):2475-9.
4. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. *Annu Rev Microbiol.* 1995;49:711-45.
5. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. *Science.* 1999;284(5418):1318-22.
6. Donlan RM. Biofilms: Microbial life on surfaces. *Emerg Infect Dis.* 2002;8(9):881-90.
7. Fanning S, Mitchell AP. Fungal biofilms. *PLoS Pathog.* 2012;8(4):e1002585.
8. Finkel JS, Mitchell AP. Genetic control of *Candida albicans* biofilm development. *Nat Rev Microbiol.* 2011;9(2):109-18.
9. Jagdish Chander. *Textbook of Medical Mycology.* 2nd ed. New Delhi: Mehta Publisher;2009.
10. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. *Clin Infect Dis.* 2012;54(8):1110-22.
11. Cauda R. Candidaemia in patients with an inserted medical device. *Drugs.* 2009;69 Suppl 1:33-8.
12. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev.* 2002; 15(2):167-93.
13. Kojic EM, Darouiche RO. *Candida* infections of medical devices. *Clin Microbiol Rev.* 2004;17(2):255-67.
14. Seddiki SM, Boucherit-Otmani Z, Boucherit K, Badsji-Amir S, Taleb M, Kunkel D. Assessment of the types of catheter infectivity caused by *Candida* species and their biofilm formation: First study in an intensive care unit in Algeria. *Int J Gen Med.* 2013; 6:1-7.
15. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, et al. Biofilm production by isolates of *Candida* species recovered from nonneutropenic patients: Comparison of bloodstream isolates from other sources. *J Clin Microbiol.* 2002;40(4):1244-8.
16. Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. *Clin Microbiol Infect.* 2015;21(1):S1-S25.
17. Mukherjee PK, Zhou G, Munyon R, Ghannoum MA. *Candida* biofilm: a well-designed protected environment. *Med Mycol.* 2005;43(3):191-208.
18. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen *Candida albicans*: development, architecture, and drug resistance. *J Bacteriol.* 2001; 183(18):5385-94.
19. Douglas LJ. *Candida* biofilms and their role in infection. *Trends Microbiol.* 2003;11(1):30-6.

20. Hawser SP, Douglas LJ. Biofilm formation by *Candida* species on the surface of catheter materials in vitro. *Infect Immun*. 1994;62(3):915-21.
21. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, Köhler JR, et al. Dispersion as an important step in the *Candida albicans* biofilm developmental cycle. *PLoS Pathog*. 2010;6(3):e1000828.
22. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. *Candida* biofilms: An update. *Eukaryotic cell*. 2005;4(4):633-8.
23. Tchekmedyan NS, Newman K, Moody MR, Costerton JW, Aisner J, Schimpff SC, et al. Special studies of the Hickman catheter of a patient with recurrent bacteremia and candidemia. *Am J Med Sci*. 1986; 291(6):419-24.
24. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: From the natural environment to infectious diseases. *Nat Rev Microbiol*. 2004; 2(2):95-108.
25. Hall-Stoodley L, Stoodley P. Developmental regulation of microbial biofilms. *Curr Opin Biotechnol*. 2002;13(3):228-33.
26. Kolenbrander PE. Oral microbial communities: biofilms, interactions, and genetic systems. *Annu Rev Microbiol*. 2000;54:413-37.
27. Estivill D, Arias A, Torres-Lana A, Carrillo-Munoz AJ, Arevalo MP. Biofilm formation by five species of *Candida* on three clinical materials. *J Microbiol Methods*. 2011;86(2):238-42.
28. Richards S, Russell C. The effect of sucrose on the colonization of acrylic by *Candida albicans* in pure and mixed culture in an artificial mouth. *J Appl Bacteriol*. 1987;62(5):421-7.
29. Swindell K, Lattif AA, Chandra J, Mukherjee PK, Ghannoum MA. Parenteral lipid emulsion induces germination of *Candida albicans* and increases biofilm formation on medical catheter surfaces. *J Infect Dis*. 2009;200(3):473-80.
30. Samaranyake YH, Cheung BP, Yau JY, Yeung SK, Samaranyake LP. Human serum promotes *Candida albicans* biofilm growth and virulence gene expression on silicone biomaterial. *PLoS One*. 2013;8(5):e62902.
31. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by *Candida albicans* and *Candida parapsilosis* on bioprosthetic surfaces. *Infect Immun*. 2002;70(2):878-88.
32. Holmes AR, Cannon RD, Jenkinson HF. Interactions of *Candida albicans* with bacteria and salivary molecules in oral biofilms. *J Ind Microbiol*. 1995;15(3):208-13.
33. Reid G, Tieszer C, Lam D. Influence of lactobacilli on the adhesion of *Staphylococcus aureus* and *Candida albicans* to fibers and epithelial cells. *J Ind Microbiol*. 1995;15(3):248-53.
34. El-Azizi MA, Starks SE, Khardori N. Interactions of *Candida albicans* with other *Candida* spp. and bacteria in the biofilms. *J Appl Microbiol*. 2004;96(5):1067-73.
35. Park SJ, Han KH, Park JY, Choi SJ, Lee KH. Influence of bacterial presence on biofilm formation of *Candida albicans*. *Yonsei Med J*. 2014;55(2):449-58.
36. Vilchez R, Lemme A, Ballhausen B, Thiel V, Schulz S, Jansen R, et al. *Streptococcus mutans* inhibits *Candida albicans* hyphal formation by the fatty acid signaling molecule trans-2-decenoic acid (SDSF). *Chem BioChem*. 2010;11(11):1552-62.
37. Mear JB, Kipnis E, Faure E, Dessein R, Schurtz G, Faure K, et al. *Candida albicans* and *Pseudomonas aeruginosa* interactions: more than an opportunistic criminal association? *Med Mal Infect*. 2013;43(4):146-51.
38. Morales DK, Grahl N, Okegbe C, Dietrich LE, Jacobs NJ, Hogan DA. Control of *Candida albicans* metabolism and biofilm formation by *Pseudomonas aeruginosa* phenazines. *MBio*. 2013;4(1):e00526-12.
39. Kelly MT, MacCallum DM, Clancy SD, Odds FC, Brown AJ, Butler G. The *Candida albicans* CaACE2 gene affects morphogenesis, adherence and virulence. *Mol Microbiol*. 2004;53(3):969-83.
40. Granger BL, Flenniken ML, Davis DA, Mitchell AP, Cutler JE. Yeast wall protein 1 of *Candida albicans*. *Microbiology*. 2005;151(Pt 5):1: 631-44.
41. Orsi CF, Borghi E, Colombari B, Neglia RG, Quaglino D, Ardizzoni A, et al. Impact of *Candida albicans* hyphal wall protein 1 (HWP1) genotype on biofilm production and fungal susceptibility to microglial cells. *Microb Pathog*. 2014;69-70:20-7.
42. Melo AS, Padovan AC, Serafim RC, Puzer L, Carmona AK, Juliano Neto L, et al. The *Candida albicans* AAA ATPase homologue of *Saccharomyces cerevisiae* Rix7p (YLL034c) is essential for proper morphology, biofilm formation and activity of secreted aspartyl proteinases. *Genet Mol Res*. 2006;5(4):664-87.
43. Dranginis AM, Rauceo JM, Coronado JE, Lipke PN. A biochemical guide to yeast adhesins: glycoproteins for social and antisocial occasions. *Microbiol Mol Biol Rev*. 2007;71(2):282-94.
44. Singh V, Satheesh SV, Raghavendra ML, Sadhale PP. The key enzyme in galactose metabolism, UDP-galactose-4-epimerase, affects cell-wall integrity and morphology in *Candida albicans* even in the absence of galactose. *Fungal Genet Biol*. 2007;44(6):563-74.
45. Bernardo SM, Khaliq Z, Kot J, Jones JK, Lee SA. *Candida albicans* VPS1 contributes to protease secretion, filamentation, and biofilm formation. *Fungal Genet Biol*. 2008;45(6):861-77.
46. Bernardo SM, Lee SA. *Candida albicans* SUR7 contributes to secretion, biofilm formation, and macrophage killing. *BMC Microbiol*. 2010;10:133.
47. Ferreira C, Silva S, Faria-Oliveira F, Pinho E, Henriques M, Lucas C. *Candida albicans* virulence and drug-resistance requires the O-acyltransferase Gup1p. *BMC Microbiol*. 2010;10:238.
48. Palanisamy SK, Ramirez MA, Lorenz M, Lee SA. *Candida albicans* PEP12 is required for biofilm integrity and in vivo virulence. *Eukaryot Cell*. 2010;9(2):266-77.
49. Giacometti R1, Kronberg F, Biondi RM, Passeron S. *Candida albicans* Tpk1p and Tpk2p isoforms differentially regulate pseudohyphal development, biofilm structure, cell aggregation and adhesins expression. *Yeast*. 2011;28(4):293-308.
50. Cleary IA, Lazzell AL, Monteagudo C, Thomas DP, Saville SP. BRG1 and NRG1 form a novel feedback circuit regulating *Candida albicans* hypha formation and virulence. *Mol Microbiol*. 2012; 85(3):557-73.
51. Banerjee M, Uppuluri P, Zhao XR, Carlisle PL, Vipulanandan G, Villar CC, et al. Expression of UME6, a key regulator of *Candida albicans* hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. *Eukaryot Cell*. 2013;12(2):224-32.
52. Raines SM, Rane HS, Bernardo SM, Binder JL, Lee SA, Parra KJ. Deletion of vacuolar proton-translocating ATPase V(o)a isoforms clarifies the role of vacuolar pH as a determinant of virulence-associated traits in *Candida albicans*. *J Biol Chem*. 2013; 288(9):6190-201.
53. Herrero-de-Dios C, Alonso-Monge R, Pla J. The lack of upstream elements of the Cek1 and Hog1 mediated pathways leads to a synthetic lethal phenotype upon osmotic stress in *Candida albicans*. *Fungal Genet Biol*. 2014; 69:31-42.
54. Pannanusorn S, Ramirez-Zavala B, Lunsdorf H, Agerberth B, Morschhauser J, Romling U. Characterization of biofilm formation and the role of BCR1 in clinical isolates of *Candida parapsilosis*. *Eukaryot Cell*. 2014;13(4):438-51.
55. Tan X, Fuchs BB, Wang Y, Chen W, Yuen GJ, Chen RB, et al. The role of *Candida albicans* SPT20 in filamentation, biofilm formation and pathogenesis. *PLoS One*. 2014;9(4):e94468.
56. Zhang B, Yu Q, Jia C, Wang Y, Xiao C, Dong Y, et al. The actin-related protein Sac1 is required for morphogenesis and cell wall integrity in *Candida albicans*. *Fungal Genet Biol*. 2015;81:261-70.

57. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, et al. A recently evolved transcriptional network controls biofilm development in *Candida albicans*. *Cell*. 2012;148(1-2):126-38.
58. Nobile CJ, Nett JE, Hernday AD, Homann OR, Deneault JS, Nantel A, et al. Biofilm matrix regulation by *Candida albicans* Zap1. *PLoS Biol*. 2009;7(6):e1000133.
59. Taff HT, Nett JE, Zarnowski R, Ross KM, Hiram Sanchez, Cain MT, et al. A *Candida* biofilm-induced pathway for matrix glucan delivery: Implications for drug resistance. *PLoS Pathog*. 2012;8(8):e1002848.
60. Xie Z, Thompson A, Sobue T, Helena Kashleva, Hongbin Xu, John Vasilakos, et al. *Candida albicans* biofilms do not trigger active oxygen species and evade neutrophil killing. *J Infect Dis*. 2012;206(12):1936-45.
61. Nigam S, Ciccoli R, Ivanov I, Szczepanski M, Deva R. On mechanism of quorum sensing in *Candida albicans* by 3(R)-hydroxy-tetradecanoic acid. *Curr Microbiol*. 2011;62(1):55-63.
62. Yu LH, Wei X, Ma M, Chen XJ, Xu SB. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in *Candida albicans* biofilm. *Antimicrob Agents Chemother*. 2012;56(2):770-5.
63. Tian J, Weng LX, Zhang YQ, Wang LH. BDSF inhibits *Candida albicans* adherence to urinary catheters. *Microb Pathog*. 2013;64:33-8.
64. Yeater KM, Chandra J, Cheng G, Mukherjee PK, Zhao X, Rodriguez-Zas SL, et al. Temporal analysis of *Candida albicans* gene expression during biofilm development. *Microbiology*. 2007;153(Pt 8):2373-85.
65. Bonhomme J, Chauvel M, Goyard S, Roux P, Rossignol T, d'Enfert C. Contribution of the glycolytic flux and hypoxia adaptation to efficient biofilm formation by *Candida albicans*. *Mol Microbiol*. 2011;80(4):995-1013.
66. Baillie GS, Douglas LJ. *Candida* biofilms and their susceptibility to antifungal agents. *Methods Enzymol*. 1999;310:644-56.
67. Baillie GS, Douglas LJ. Effect of growth rate on resistance of *Candida albicans* biofilms to antifungal agents. *Antimicrob Agents Chemother*. 1998;42(8):1900-05.
68. Hawser SP, Douglas LJ. Resistance of *Candida albicans* biofilms to antifungal agents in vitro. *Antimicrob Agents Chemother*. 1995;39(9):2128-33.
69. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of *Candida* biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. *Antimicrob Agents Chemother*. 2002;46(6):1773-80.
70. Bernhardt H, Knoke M, Bernhardt J. Changes in *Candida albicans* colonization and morphology under influence of voriconazole. *Mycoses*. 2003;46(9-10):370-4.
71. Cateau E, Levasseur P, Borgonovi M, Imbert C. The effect of aminocandin (HMR 3270) on the in-vitro adherence of *Candida albicans* to polystyrene surfaces coated with extracellular matrix proteins or fibronectin. *Clin Microbiol Infect*. 2007;13(3):311-5.
72. Kaneko Y, Miyagawa S, Takeda O, Hakariya M, Matsumoto S, Ohno H, et al. Real-time microscopic observation of *Candida* biofilm development and effects due to micafungin and fluconazole. *Antimicrob Agents Chemother*. 2013;57(5):2226-30.
73. Suci PA, Tyler BJ. Action of chlorhexidine digluconate against yeast and filamentous forms in an early-stage *Candida albicans* biofilm. *Antimicrob Agents Chemother*. 2002;46(11):3522-31.
74. Bersan SM, Galvao LC, Goes VF, Sartoratto A, Figueira GM, Rehder VL, et al. Action of essential oils from Brazilian native and exotic medicinal species on oral biofilms. *BMC Complement Altern Med*. 2014;14:451.
75. da Silva PM, Acosta EJ, Pinto Lde R, Graeff M, Spolidorio DM, Almeida RS, et al. Microscopical analysis of *Candida albicans* biofilms on heat-polymerised acrylic resin after chlorhexidine gluconate and sodium hypochlorite treatments. *Mycoses*. 2011;54(6):712-7.
76. Fazly A, Jain C, Dehner AC, Issi L, Lilly EA, Ali A, et al. Chemical screening identifies filastatin, a small molecule inhibitor of *Candida albicans* adhesion, morphogenesis, and pathogenesis. *Proc Natl Acad Sci USA*. 2013;110(33):13594-9.
77. Traboulsi RS, Mukherjee PK, Chandra J, Salata RA, Jurevic R, Ghannoum MA. Gentian violet exhibits activity against biofilms formed by oral *Candida* isolates obtained from HIV-infected patients. *Antimicrob Agents Chemother*. 2011;55(6):3043-5.
78. Villa F, Pitts B, Stewart PS, Giussani B, Roncoroni S, Albanese D, et al. Efficacy of zosteric acid sodium salt on the yeast biofilm model *Candida albicans*. *Microb Ecol*. 2011;62(3):584-98.
79. Basso FG, Oliveira CF, Fontana A, Kurachi C, Bagnato VS, Spolidório DM, et al. In vitro effect of low-level laser therapy on typical oral microbial biofilms. *Braz Dent J*. 2011;22(6):502-10.
80. Machado-de-Sena RM, Correa L, Kato IT, Prates RA, Senna AM, Santos CC, et al. Photodynamic therapy has antifungal effect and reduces inflammatory signals in *Candida albicans*-induced murine vaginitis. *Photodiagnosis Photodyn Ther*. 2014;11(3):275-82.
81. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonization of catheters. *Antimicrob Agents Chemother*. 1995;39(11):2397-400.
82. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in *Candida albicans* biofilms: phase-specific role of efflux pumps and membrane sterols. *Infect Immun*. 2003;71(8):4333-40.
83. LaFleur MD, Kumamoto CA, Lewis K. *Candida albicans* biofilms produce antifungal-tolerant persister cells. *Antimicrob Agents Chemother*. 2006;50(11):3839-46.
84. LA Merme, M Allon, E Bouza, Donald E Craven, Patricia Flynn, Naomi PO'Grady, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. *Clin Infect Dis*. 2009;49(1):1-45.
85. Carratalà J. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. *Clin Microbiol Infect*. 2002;8(5):282-9.
86. Teughels W, Van Assche N, Sliepen I, Quirynen M. Effect of material characteristics and/or surface topography on biofilm development. *Clin Oral Implants Res*. 2006;17 Suppl 2:68-81.
87. Radford DR, Sweet SP, Challacombe SJ, Walter JD. Adherence of *Candida albicans* to denture-base materials with different surface finishes. *J Dent*. 1998;26(7):577-83.
88. Ramage G, Saville SP, Wickes BL, L'opez-Ribot JL. Inhibition of *Candida albicans* biofilm formation by farnesol, a quorum-sensing molecule. *Appl Environment Microbiol*. 2002;68(11):5459-63.
89. Alem MAS, Oteef MDY, Flowers TH, Douglas LJ. Production of tyrosol by *Candida albicans* biofilms and its role in quorum sensing and biofilm development. *Eukaryotic Cell*. 2006;5(10):1770-9.
90. Hogan DA, Vik A, Kolter R. A *Pseudomonas aeruginosa* quorum-sensing molecule influences *Candida albicans* morphology. *Mol Microbiol*. 2004;54(5):1212-23.
91. Valle J, Da Re S, Henry M, Fontaine T, Balestrino D, Latour-Lambert P, et al. Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. *Proc Nati Acad Sci USA*. 2006;103(33):12558-63.
92. Njoroge J, Sperandio V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. *EMBO Mol Med*. 2009;1(4):201-10.

93. Macedo AJ, Abraham WR. Can infectious biofilm be controlled by blocking bacterial communication? *Medicinal Chem.* 2009;5(6):517-28.
94. van der Meer JW, van de Veerdonk FL, Joosten LA, Kullberg BJ, Netea MG. Severe *Candida* spp. infections: new insights into natural immunity. *Int J Antimicrob Agents.* 2010;36 Suppl 2:S58-62.
95. Wozniak KL, Palmer G, Kutner R, Fidel PL. Immunotherapeutic approaches to enhance protective immunity against *Candida* vaginitis. *Med Mycol.* 2005;43(7):589-601.
96. Katragkou A, Kruhlak MJ, Simitsopoulou M, Chatzimoschou A, Taparkou A, Cotten CJ, et al. Interactions between human phagocytes and *Candida albicans* biofilms alone and in combination with antifungal agents. *J Infect Dis.* 2010;201(12):1941-9.
97. Katragkou A, Chatzimoschou A, Simitsopoulou M, Georgiadou E, Roilides E. Additive antifungal activity of anidulafungin and human neutrophils against *Candida parapsilosis* biofilms. *J Antimicrob Chemother.* 2011;66(3):588-91.
98. Nett J, Lincoln L, Marchillo K, Andes D. β -1,3 glucan as a test for central venous catheter biofilm infection. *J Infect Dis.* 2007;195(11):1705-12.
99. van de Veerdonk FL, Netea MG, Joosten LA, van der Meer JW, Kullberg BJ. Novel strategies for the prevention and treatment of *Candida* infections: the potential of immunotherapy. *FEMS Microbiol Rev.* 2010;34(6):1063-75.
100. Fujibayashi T, Nakamura M, Tominaga A, Satoh N, Kawarai T, Narisawa N, et al. Effects of IgY against *Candida albicans* and *Candida* spp. Adherence and Biofilm Formation. *Jpn J Infect Dis.* 2009;62(5):337-42.
101. Nett J, Andes DR. *Candida albicans* biofilm development, modeling a host-pathogen interaction. *Curr Opin Microbiol.* 2006;9(4):340-5.
102. Mukherjee PK, Chand DV, Chandra J, Anderson JM, Ghannoum MA. Shear stress modulates the thickness and architecture of *Candida albicans* biofilms in a phase-dependent manner. *Mycoses.* 2009;52(5):440-6.
103. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ, et al. Antifungal resistance of *Candida* biofilms formed on denture acrylic in vitro. *J Dent Res.* 2001;80(3):903-8.
104. Imamura Y, Chandra J, Mukherjee PK, Ali Abdul Lattif, Loretta B. Szczotka-Flynn, Eric Pearlman, et al. *Fusarium* and *Candida albicans* biofilms on soft contact lenses: Model development, influence of lens type and susceptibility to lens care solutions. *Antimicrob Agents Chemother.* 2008;52(1):171-82.
105. Nikawa H, Yamamoto T, Hamada T. Effect of components of resilient denture-lining materials on the growth, acid production and colonization of *Candida albicans*. *J Oral Rehabil.* 1995;22(11):817-24.
106. Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. Biofilm formation by *Candida dubliniensis*. *J Clin Microbiol.* 2001;39(9):3234-40.
107. van der Mei HC, Free RH, Elving GJ, van Weissenbruch R, Albers FW, Busscher HJ. Effect of probiotic bacteria on prevalence of yeasts in oropharyngeal biofilms on silicone rubber voice prostheses in vitro. *J Med Microbiol.* 2000;49(8):713-8.